Tandem Diabetes Care announced that its t:slim X2 insulin pump is now compatible with Abbott’s FreeStyle Libre 3 Plus continuous glucose monitoring sensor in the US.
The FreeStyle Libre 3 Plus sensor offers a 15-day wear time, providing automatic glucose readings every minute directly to the pump.
The t:slim X2 insulin pump leverages Control-IQ+ technology, an advanced hybrid closed-loop algorithm that adjusts insulin every five minutes based on predicted glucose levels.
It features the AutoBolus function, which calculates and delivers a correction bolus to address missed meal boluses, thereby extending its benefits to more diabetes patients.
Their compatibility allows users to access the data through the Tandem t:slim mobile app, offering multiple convenient options for monitoring glucose trends.
The development marks a significant step in enhancing personalisation and choice for individuals managing diabetes.
Tandem Diabetes Care Chief Medical Officer Jordan Pinsker said: “Diabetes management is not one-size-fits-all, and it is critical for people living with diabetes to be able to personalise their AID systems to fit their unique healthcare and lifestyle needs.
“The American Diabetes Association recommends AID systems as the preferred insulin delivery method in people with type 1 and other types of insulin-deficient diabetes.
“This integration with Abbott’s latest generation sensor allows even more CGM users to access the life-changing benefits of our Control-IQ+ technology.”
Last year, Tandem confirmed that t:slim X2 insulin pump users can access full compatibility with both the Dexcom G7 and Dexcom G6 continuous glucose monitoring systems.
Recently, the medical device company entered a partnership with Abbott to develop and commercialise integrated diabetes solutions.
The collaboration will combine Abbott’s dual glucose-ketone sensor with Tandem’s insulin delivery systems, aiming to offer more options for diabetes management.
The Abbott sensor, currently under development, will integrate glucose and ketone sensing technology to help detect early rise in ketone, preventing diabetic ketoacidosis.
Tandem Diabetes Care president and CEO John Sheridan said: “This is an exciting first step in our strategy to connect Tandem’s portfolio of insulin pumps to Abbott’s FreeStyle Libre 3 Plus sensors worldwide.
“We look forward to expanding access to our t:slim X2 users outside of the US beginning later this year.”
